Latest News about CSE:INNO
Recent news which mentions CSE:INNO
From Benzinga
This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
April 23, 2024
From Benzinga
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
April 02, 2024
From Benzinga
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
February 13, 2024
From Benzinga
From Benzinga